Literature DB >> 15815891

[Sense and nonsense in antibiotic therapy for respiratory tract infections].

W Domej1, E Flögel, G P Tilz, U Demel.   

Abstract

Whether an antibiotic successfully eradicates pathogens depends on the pathogens involved, on pharmacokinetics and bioavailability in the target tissue, and on the antimicrobial resistance of the pathogen. Other determinants are drug interactions, individual risk factors, age and compliance with respect to correct dosage and duration of therapy. In many cases, antimicrobial therapy is begun on an empirical basis, because the responsible pathogen can be identified in only half of all respiratory infections. The eradication of the pathogen has to be the first aim if treatment is to be curative and the development of resistance prevented. Long-term prevention of antimicrobial resistance will require a more critical prospective evaluation of the prescription of antibiotics. This paper considers rational and irrational measures in the antimicrobial therapy of respiratory infections.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15815891     DOI: 10.1007/s00108-005-1397-6

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  29 in total

Review 1.  [What is reliable in antibiotic therapy of inflammatory bronchopulmonary diseases?].

Authors:  U Koehler; T Podszus; P von Wichert
Journal:  Internist (Berl)       Date:  1998-12       Impact factor: 0.743

Review 2.  Nonresponses and treatment failures with conventional empiric regimens in patients with community-acquired pneumonia.

Authors:  James S Tan
Journal:  Infect Dis Clin North Am       Date:  2004-12       Impact factor: 5.982

3.  Community-acquired pneumonia-optimizing antibiotic usage.

Authors:  Douglas B Schwartz
Journal:  Curr Opin Pulm Med       Date:  2004-11       Impact factor: 3.155

4.  Reducing antibiotic use in children: a randomized trial in 12 practices.

Authors:  J A Finkelstein; R L Davis; S F Dowell; J P Metlay; S B Soumerai; S L Rifas-Shiman; M Higham; Z Miller; I Miroshnik; A Pedan; R Platt
Journal:  Pediatrics       Date:  2001-07       Impact factor: 7.124

5.  Risk factors of treatment failure in community acquired pneumonia: implications for disease outcome.

Authors:  R Menéndez; A Torres; R Zalacaín; J Aspa; J J Martín Villasclaras; L Borderías; J M Benítez Moya; J Ruiz-Manzano; F Rodríguez de Castro; J Blanquer; D Pérez; C Puzo; F Sánchez Gascón; J Gallardo; C Alvarez; L Molinos
Journal:  Thorax       Date:  2004-11       Impact factor: 9.139

6.  Development of macrolide-resistance and comparative activity of telithromycin in streptococci in Austria, 1996-2002.

Authors:  Astrid Buxbaum; Sabine Forsthuber; Robert Sauermann; Rainer Gattringer; Wolfgang Graninger; Apostolos Georgopoulos
Journal:  Int J Antimicrob Agents       Date:  2004-10       Impact factor: 5.283

7.  Effectiveness of a multiple intervention to reduce antibiotic prescribing for respiratory tract symptoms in primary care: randomised controlled trial.

Authors:  Ineke Welschen; Marijke M Kuyvenhoven; Arno W Hoes; Theo J M Verheij
Journal:  BMJ       Date:  2004-08-05

Review 8.  Adherence to guidelines for community-acquired pneumonia: does it decrease cost of care?

Authors:  Patricia D Brown
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

9.  Influence of penicillin resistance on outcome in adult patients with invasive pneumococcal pneumonia: is penicillin useful against intermediately resistant strains?

Authors:  Vicenç Falcó; Benito Almirante; Queralt Jordano; Laura Calonge; Oscar del Valle; Carles Pigrau; Ana María Planes; Joan Gavaldà; Albert Pahissa
Journal:  J Antimicrob Chemother       Date:  2004-06-23       Impact factor: 5.790

Review 10.  Diagnostic test for etiologic agents of community-acquired pneumonia.

Authors:  John G Bartlett
Journal:  Infect Dis Clin North Am       Date:  2004-12       Impact factor: 5.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.